General Meetings
Annual General Meeting 2025
The Annual General Meeting in Swedish Orphan Biovitrum AB (publ) will be held on Thursday May 8 at 10.00 a.m. at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
Proposals:
Shareholders who wish to have a matter addressed by the Annual General Meeting or submit proposals to Swedish Orphan Biovitrum’s Nomination Committee shall submit their proposals to the General Counsel at the following address:
Swedish Orphan Biovitrum AB (publ)
Attn: Torbjörn Hallberg
SE-112 76 Stockholm
Sweden
Considering the scheduled date for publishing the Notice of the Annual General Meeting, proposals have to be received by the Company no later than Thursday, March 20, 2025 and proposals to the Nomination Committee no later than Friday, February 28, 2025. This is in order to have sufficient time for including them in the Annual General Meeting Notice and Agenda, respectively.
Annual General Meeting 2024
Annual General Meeting 2024
The Annual General Meeting in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, was held on Tuesday, 14 May 2024.
The shareholders were able to exercise their voting rights at the Annual General Meeting also by postal voting.
At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows:
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits.
The Board members and the chief executive officer were discharged from liability for the financial year 2023.
Election of Board of Directors, remuneration to the Directors, election of Auditor and remuneration to the Auditor
The ordinary Board members Christophe Bourdon, Annette Clancy, Helena Saxon, Staffan Schüberg, Filippa Stenberg and Anders Ullman were re-elected as Board members and Zlatko Rihter was elected as new Board member for the period until the end of the next AGM. Annette Clancy was re elected as chair of the Board of Directors.
Ernst & Young AB was re-elected as auditor of Sobi for the period until the end of the next AGM.
The AGM approved the remuneration to the Board of Directors and the Auditor in accordance with the Nomination Committee’s proposal.
Remuneration report, guidelines for executive remuneration, long-term incentive programmes, authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants, and transfer of own shares
The AGM resolved to approve the Board of Directors’ remuneration report.
The AGM resolved to approve the Board of Directors’ proposal for guidelines for executive remuneration.
The AGM resolved to approve the Board of Directors’ proposal to implement long-term incentive programmes, consisting of hedging arrangements in respect of the programmes by way of directed issues of no more than 1,641,103 series C shares in the aggregate, authorisation for the Board of Directors to resolve on a repurchase of all issued series C shares and transfer of no more than 3,156,277 own common shares in the aggregate to participants of the programmes.
The AGM approved the Board of Directors’ proposal regarding the authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants. The number of shares that may be issued, the number of shares that convertible bonds may be converted into and the number of shares that may be subscribed for by the exercise of warrants, may not exceed 39,370,000 shares in total.
The Board of Directors’ proposal regarding transfer of no more than 1,006,742 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the incentive programmes 2020 and 2021, was also approved by the AGM.
For full details on each proposal adopted by the AGM, please refer to “Related information” on this page.
Related information
- Minutes from Annual General Meeting 2024
- Notice to Annual General Meeting 2024
- Proposal to AGM by the Nomination Committee
- Motivated opinion re. proposals by the Nomination Committee
- Information about proposed members of the Board
- Remuneration report 2023 (item 16)
- Proposal re. Guidelines for Executive Remuneration (item 17)
- Proposal re. implementation of a long-term incentive programme (item 18)
- Proposal re. approval to authorise the issuance of new shares and/or convertible bonds and/or warrants (item 19)
- Proposal re. transfer of own shares (item 20)
- Board’s Statement Swedish Companies Act 19:22
- Auditor’s Statement Swedish Companies Act 8:54
- Postal Voting Form
- Proxy Form
- CEO’s presentation at the AGM 2024
Extraordinary General Meeting 2023
The Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, was held on Tuesday, 15 August 2023.
The shareholders were able to exercise their voting rights at the Meeting also by postal voting in accordance with the regulations in Sobi’s Articles of Association.
At the Extraordinary General Meeting, the shareholders, in accordance with the proposed resolutions, resolved as follows:
Authorisation for the Board of Directors to resolve on a new issue of common shares
The EGM resolved to authorise the Board of Directors to, during the period up to the Annual General Meeting 2024, resolve on issue of new common shares with preferential rights for the company’s shareholders. The total number of shares that may be issued shall amount to the number of shares that corresponds to issue proceeds of approximately SEK 6,000,000,000 and shall be within the limits of the share capital. The purpose of the authorisation is to repay part of the bridge loan that partly finances the company’s acquisition of CTI BioPharma Corp. Other terms and conditions for the new share issue shall be determined by the Board of Directors.
Authorisation for the Board of Directors to resolve on a directed issue of series C shares and authorisation for the Board of Directors to resolve on repurchase of issued series C shares
The EGM resolved to authorise the Board of Directors to, during the period up to the Annual General Meeting 2024, (I) resolve on a directed issue of no more than 700,000 series C shares and (II) resolve on repurchase of all issued class C shares. The purpose of the authorisation to resolve on new issue of series C shares and the proposed possibility to repurchase own shares is that Sobi shall be able to fulfil its obligations under outstanding incentive programmes in a cost-effective manner after the recalculation of the number of common shares in Sobi that may be delivered under each programme as a result of the rights issue that Sobi intends to carry out.
For full details on each proposal adopted by the Extraordinary General Meeting, please refer to “Related information” on this page.
Related information
Annual General Meeting 2023
The Annual General Meeting in Swedish Orphan Biovitrum AB (publ) (Sobi™) Reg. No. 556038-9321, was held on Tuesday, 9 May 2023.
The shareholders were able to exercise their voting rights at the Meeting also by postal voting in accordance with the regulations in Sobi’s Articles of Association.
At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows:
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits.
The Board members and the chief executive officer were discharged from liability for the financial year 2022.
Election of Board of Directors, remuneration to the Directors, election of Auditor and remuneration to the Auditor
The ordinary Board members Annette Clancy, Bo Jesper Hansen, Helena Saxon, Staffan Schüberg and Filippa Stenberg were re-elected as Board members and Christophe Bourdon and Anders Ullman were elected as new Board members for the period until the end of the next AGM. Bo Jesper Hansen was elected as new chairman of the Board of Directors.
The AGM approved the remuneration to the Board of Directors and the Auditor in accordance with the Nomination Committee’s proposal.
Ernst & Young AB was re-elected as auditor of Sobi for the period until the end of the next AGM.
Report for remuneration for senior executives, long-term incentive programmes, authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants, and transfer of own shares
The AGM resolved to approve the Board of Directors’ report for remuneration for senior executives.
The AGM resolved to approve the Board of Directors’ proposal regarding hedging arrangements in respect of the Management Programme by way of a directed issue of no more than 1,532,014 series C shares, authorisation for the Board of Directors to resolve on a repurchase of all issued series C shares and transfer of no more than 3,060,672 own common shares to participants of the Management Programme. As regards the All Employee Programme the AGM resolved to approve the Board of Directors’ proposal regarding hedging arrangement by way of an equity swap agreement with a third party, whereby the third party in its own name shall be entitled to acquire and transfer common shares in Sobi to participants of the All Employee Programme.
The AGM approved the Board of Directors’ proposal regarding the approval to authorise the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants. The number of shares that may be issued, the number of shares that convertible bonds may be converted into and the number of shares that may be subscribed for by the exercise of warrants, may not exceed 34,400,000 shares in total.
The Board of Directors’ proposal regarding transfer of no more than 556,986 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the incentive programmes 2019 and 2020, was also approved by the AGM.
For full details on each proposal adopted by the AGM, please refer to “Related information” on this page.
Related information
- Minutes from Annual General Meeting 2023
- Notice to Annual General Meeting 2023
- Proposal to AGM by the Nomination Committee
- Motivated opinion re. proposals by the Nomination Committee
- Information about proposed members of the Board
- Remuneration report 2022
- Proposal re. implementation of a long-term incentive programme (item 17)
- Proposal re. approval to authorise the issuance of new shares and/or convertible bonds and/or warrants (item 18)
- Proposal re. transfer of own shares (item 19)
- Board’s Statement Swedish Companies Act 19:22
- Postal Voting Form
- Proxy Form
- Auditor’s Statement Swedish Companies Act 8:54
- CEO’s presentation at the AGM 2023
Annual General Meeting 2022
The Annual General Meeting in Swedish Orphan Biovitrum AB (publ) (Sobi™) Reg. No. 556038-9321, was held on Tuesday, 10 May 2022.
Due to the coronavirus, the shareholders were able to exercise their voting rights at the Meeting also by postal voting in accordance with the regulations in Sobi’s Articles of Association
At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows:
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits.
The Board members and the chief executive officer were discharged from liability for the financial year 2021.
Election of Board of Directors, remuneration to the Directors, election of Auditor and remuneration to the Auditor
The ordinary Board members Håkan Björklund, Annette Clancy, Matthew Gantz, Helena Saxon, Staffan Schüberg and Filippa Stenberg were re-elected as Board members and Bo Jesper Hansen was elected as new Board member for the period until the end of the next AGM. Håkan Björklund was re-elected chairman of the Board of Directors.
The AGM approved the remuneration to the Board of Directors and the Auditor in accordance with the Nomination Committee’s proposal.
Ernst & Young AB was re-elected as auditor of Sobi for the period until the end of the next AGM.
Report for remuneration for senior executives, long-term incentive programmes, authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants, and transfer of own shares
The AGM resolved to approve the Board of Directors’ report for remuneration for senior executives.
The AGM also approved the Board of Directors’ proposal regarding the implementation of long-term incentive programmes, and hedging arrangements in respect of the programmes including a directed issue of no more than 2,690,287 series C shares, authorisation for the Board of Directors to decide on a repurchase of all issued series C shares and transfers of no more than 2,225,247 own common shares to program participants.
The AGM also approved the Board of Directors’ proposal regarding the approval to authorise the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants. The number of shares that may be issued, the number of shares that convertible bonds may be converted into and the number of shares that may be subscribed for by the exercise of warrants, may not exceed 34,125,000 shares in total.
The Board of Directors’ proposal regarding transfer of no more than 593,859 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Incentive Programme 2019, was also approved by the AGM.
For full details on each proposal adopted by the AGM, please refer to “Related documents” on this page.
Related information
- Minutes from Annual General Meeting 2022
- Proposal to AGM by the Nomination Committee
- Motivated opinion re. proposals by the Nomination Committee
- Information about proposed members of the Board
- Notice to Annual General Meeting 2022
- Remuneration report 2021
- Proposal re. implementation of a long-term incentive programme (item 17)
- Proposal re. approval to authorise the issuance of new shares and/or convertible bonds and/or warrants (item 18)
- Proposal re. transfer of own shares (item 19)
- Board’s Statement Swedish Companies Act 19:22
- Proxy Form
- Postal Voting Form
- Auditor’s Statement Swedish Companies Act 8:54
- CEO’s presentation at the AGM 2022
Annual General Meeting 2021
The Annual General Meeting (AGM) in Swedish Orphan Biovitrum AB (publ), (Sobi™), Reg. No. 556038-9321, was held on Tuesday 4 May 2021. Due to the coronavirus and in order to reduce the risk of spreading the virus, the AGM was only conducted by way of postal vote pursuant to temporary legislation being in effect in 2021.
The AGM voted in favour of the resolutions proposed at the meeting, including:
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits of SEK 16,232,740,050.
The Board members and the chief executive officer were discharged from liability for the financial year 2020.
Election of Board of Directors, remuneration to the Directors, election of Auditor and remuneration to the Auditor
The ordinary Board members Håkan Björklund, Annette Clancy, Matthew Gantz, Helena Saxon, Staffan Schüberg and Elisabeth Svanberg were re-elected as Board members and Filippa Stenberg and Anders Ullman were elected as new Board members for the period until the end of the next AGM. Håkan Björklund was re-elected chairman of the Board of Directors.
The AGM approved the remuneration to the Board of Directors and the Auditor in accordance with the Nomination Committee’s proposal.
Ernst & Young AB was re-elected as auditor of Sobi for the period until the end of the next AGM.
Report for remuneration for senior executives, amendments of the articles of association, long-term incentive programmes, authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants, and transfer of own shares
The AGM resolved to approve the Board of Directors’ report for renumeration for senior executives.
The AGM also approved the Board of Directors proposal regarding amendments of the articles of association.
The AGM also approved the Board of Directors’ proposal regarding the implementation of long term incentive programmes, and hedging arrangements in respect of the programmes including a directed issue of no more than 3,298,984 series C shares, authorisation for the Board of Directors to decide on a repurchase of all issued series C shares and transfers of no more than 2,200,799 own common shares to program participants.
The AGM also approved the Board of Directors’ proposal regarding the approval to authorise the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants. The number of shares that may be issued, the number of shares that convertible bonds may be converted into and the number of shares that may be subscribed for by the exercise of warrants, may not exceed 33,750,000 shares in total.
The Board of Directors’ proposal regarding transfer of no more than 215,908 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Incentive Programme 2018, was also approved by the AGM.
For full details on each proposal adopted by the AGM, please refer to “Related documents” on this page.
Related information
- Minutes from Annual General Meeting 2021
- Proposal to AGM by the Nomination Committee
- Motivated opinion re. proposals by the Nomination Committee
- Information about proposed members of the Board
- Notice to Annual General Meeting 2021
- Remuneration report 2020
- Proposal re. amendments of the articles of association (item 14)
- Proposal re. implementation of a long-term incentive programme (item 15)
- Proposal re. approval to authorise the issuance of new shares and/or convertible bonds and/or warrants (item 16)
- Proposal re. transfer of own shares (item 17)
- Board’s Statement Swedish Companies Act 19:22
- Postal Voting Form
- Proxy Form
- Auditor’s Statement Swedish Companies Act 8:54
- Articles of Association adopted at the Annual General Meeting 4 May 2021
Annual General Meeting 2020
Annual General Meeting 2020
The Annual General Meeting (AGM) in Swedish Orphan Biovitrum AB (publ), (Sobi™), Reg. No. 556038-9321, was held on Wednesday, May 13 2020 at 15:00 at Stockholm City Conference Centre, Norra Latin, Drottninggatan 71B, Stockholm, Sweden.
CEO’s presentation at the AGM
The slides from CEO Guido Oelker’s presentation at the AGM is available to download under “Related documents” on this page.
The AGM voted in favour of the resolutions proposed at the meeting, including:
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits of SEK 12,569,323,779.
The board members and the chief executive officer were discharged from liability for the financial year 2019.
Election of Board of Directors, remuneration to the Directors and election of Auditor
The ordinary board members Håkan Björklund, Annette Clancy, Matthew Gantz, Lennart Johansson, Helena Saxon and Elisabeth Svanberg were re-elected as board members and Staffan Schüberg was elected as new board member for the period until the end of the next AGM. Håkan Björklund was re-elected chairman of the Board.
The AGM approved the compensation to the Board in accordance with the Nomination Committee’s proposal.
Ernst & Young AB was re-elected as auditor of Sobi for the period until the end of the next AGM.
Principles for remuneration for the management, amendments of the articles of association, long-term incentive programmes, authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants, and transfer of own shares
The AGM approved the guidelines for remuneration for the management proposed by the Board.
The AGM also approved the Board’s proposal regarding amendments of the articles of association.
The AGM also approved the Board’s proposal regarding the implementation of long term incentive programmes, and hedging arrangements in respect of the programmes including a directed issue of no more than 3,837,672 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 3,671,127 own common shares to programme participants.
The AGM also approved the Board’s proposal regarding the approval to authorise the Board to resolve on the issuance of new shares and/or convertible bonds and/or warrants. The number of shares that may be issued, the number of shares that convertible bonds may be converted into and the number of shares that may be subscribed for by the exercise of warrants, may not exceed 33,000,000 shares in total.
The Board’s proposal regarding transfer of no more than 247,655 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Incentive Programme 2017, was also approved by the AGM.
For full details on each proposal adopted by the AGM, please refer to “Related Documents” on this page.
Related information
- Proposal to AGM by the Nomination Committee
- Motivated opinion re. proposals by the Nomination Committee
- Information about proposed members of the Board
- Notice to Annual General Meeting 2020
- Proposal re. Guidelines for Executive Remuneration (item 16)
- Proposal re. amendments of the articles of association (item 17)
- Proposal re. implementation of a long-term incentive programme (item 18)
- Proposal re. approval to authorise the issuance of new shares and/or convertible bonds and/or warrants (item 19)
- Proposal re. transfer of own shares (item 20)
- Report by the Board of the Compensation & Benefits Committee’s evaluation of remuneration to the Executive Committee
- Board’s Statement Swedish Companies Act 19:22
- Proxy Form
- Auditor’s Statement Swedish Companies Act 8:54
- Advance Voting Form
- CEO’s presentation at the AGM 2020
- Minutes from Annual General Meeting 2020
- Articles of Association adopted at the Annual General Meeting 13 May 2020
Annual General Meeting 2019
The Annual General Meeting in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, was held on Thursday, 9 May, 2019 at 15:00 at Grand Hôtel, S. Blasieholmshamnen 8, Stockholm, Sweden.
CEO's presentation at the AGM
The slides from CEO Guido Oelkers’ presentation at the AGM is available to download under “Related Documents” on this page.
The AGM voted in favour of the resolutions proposed at the meeting, including:
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits of SEK 6,780,309,816.
The board members and the chief executive officer were discharged from liability for the financial year 2018.
Election of Board of Directors, remuneration to the Directors, election of Auditor and adoption of instructions and charter for the Nomination Committee
The ordinary board members David Allsop, Håkan Björklund, Annette Clancy, Matthew Gantz, Lennart Johansson, Helena Saxon, Hans GCP Shikan and Elisabeth Svanberg were re-elected as board members for the period until the end of the next AGM. Håkan Björklund was re-elected chairman of the Board.
The AGM approved the compensation to the Board in accordance with the Nomination Committee’s proposal.
Ernst & Young AB was re-elected as auditor of Sobi for the period until the end of the next AGM.
The AGM resolved to adopt instructions and charter for the Nomination Committee in accordance with the Nomination Committee’s proposal.
Principles for remuneration for the management, long-term incentive programmes, authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants, and transfer of own shares
The AGM approved the guidelines for remuneration for the management proposed by the Board.
The AGM also approved the Board’s proposal regarding the implementation of long-term incentive programmes, and hedging arrangements in respect of the programmes including a directed issue of no more than 2,462,630 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 2,673,345 own common shares to program participants.
The AGM also approved the Board’s proposal regarding the approval to authorise the Board to resolve on the issuance of new shares and/or convertible bonds and/or warrants. The number of shares that may be issued, the number of shares that convertible bonds may be converted into and the number of shares that may be subscribed for by the exercise of warrants, may not exceed 33,000,000 shares in total.
The Board’s proposal regarding transfer of no more than 85,775 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Incentive Programme 2016, was also approved by the AGM.
For full details on each proposal adopted by the AGM, please refer to “Related Documents” on this page.
Related information
- Proposal to AGM by the Nomination Committee
- Motivated opinion re. proposals by the Nomination Committee
- Information about proposed members of the Board
- Notice to Annual General Meeting 2019
- Proposal re. guidelines for remuneration for the Management (item 16)
- Proposal re. instructions and charter for the Nomination Committee (item 17)
- Proposal re. implementation of a long-term incentive programme (item 18)
- Proposal re. approval to authorise the issuance of new shares and/or convertible bonds and/or warrants (item 19)
- Proposal re. transfer of own shares (item 20)
- Report by the Board of Compensation & Benefits Committee's evaluation of remuneration to senior management
- Board's Statement Swedish Companies Act 19:22
- Proxy Form
- Auditor's Statement Swedish Companies Act 8:54
- CEO's presentation at the AGM 2019
- Minutes from Annual General Meeting 9 May 2019
Annual General Meeting 2018
The Annual General Meeting (AGM) in Swedish Orphan Biovitrum AB (publ) was held on Wednesday May 9 at 3.00 p.m. at Näringslivets Hus, Storgatan 19, Stockholm, Sweden.
CEO’s presentation at the AGM
The slides from CEO Guido Oelkers’ presentation at the AGM is available to download under “Related Documents” on this page.
The AGM voted in favour of the resolutions proposed at the meeting, including:
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits of SEK 4,486,594,396.
The board members and the chief executive officers were discharged from liability for the financial year 2017.
Election of Board of Directors, remuneration to the Directors and election of Auditor
The ordinary board members Håkan Björklund, Annette Clancy, Matthew Gantz, Lennart Johansson, Helena Saxon and Hans GCP Shikan were re-elected and David Allsop and Elisabeth Svanberg were elected as new board members for the period until the end of the next AGM. Håkan Björklund was re-elected chairman of the Board.
The AGM approved the compensation to the Board in accordance with the nomination committee’s proposal.
Ernst & Young AB was re-elected as auditor of Sobi for the period until the end of the next AGM.
Principles for remuneration for the management, long-term incentive program, authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants, and transfer of own shares
The AGM approved the guidelines for remuneration for the management proposed by the Board.
The AGM also approved the Board’s proposal regarding the implementation of a long-term incentive program, and hedging arrangements in respect of the program including a directed issue of no more than 814,409 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 1,427,269 own common shares to program participants.
The AGM also approved the Board’s proposal regarding the approval to authorise the Board to resolve on the issuance of new shares and/or convertible bonds and/or warrants. The number of shares that may be issued, the number of shares that convertible bonds may be converted into and the number of shares that may be subscribed for by the exercise of warrants, may not exceed 30,000,000 shares in total.
The Board’s proposal regarding transfer of no more than 144,808 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Share Program 2015, was also approved by the AGM.
For full details on each proposal adopted by the AGM, please refer to “Related Documents” on this page.
Related information
- Motivated opinion re. proposals ny the Nomination Committee
- Information about proposed members of the Board
- Proposal to AGM by the Nomination Committee
- Complete Notice to Annual General Meeting 2018
- Proposal guidelines for remuneration to Management (item 16)
- Proposal implementation of a longterm incentive program (item 17)
- Proposal regarding approval to authorise issuance of new shares and/or convertible bonds and/or warrants (item 18)
- Proposal transfer of own shares (item 19)
- Report by the Board of Compensation & Benefits Committee's evaluation of remuneration to senior management
- Board's Statement Swedish Compnaies Act 19:22
- Proxy Form
- Auditor's Statement Swedish Compnaies Act 8:54
- CEO's presentation at the AGM 2018
- Minutes from Annual General Meeting May 9, 2018
Annual General Meeting 2017
The Annual General Meeting (AGM) in Swedish Orphan Biovitrum AB (publ), was held on Thursday May 4, 2017 at 3.00 p.m. in Wallenbergsalen, the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm, Sweden.
CEO's presentation at the AGM
The slides from CEO Geoffrey McDonough's presentation at the AGM is available for download under "Related Documents" on this page.
The AGM voted in favour of the resolutions proposed at the meeting, including:
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits of SEK 4,794,687,847.
The board members and the chief executive officer were discharged from liability for the financial year 2016.
Election of Board of Directors, remuneration to the Directors and election of Auditor
The ordinary board members Håkan Björklund, Annette Clancy, Matthew Gantz, Lennart Johansson, Helena Saxon and Hans GCP Shikan were re-elected for the period until the end of the next AGM. Håkan Björklund was re-elected chairman of the Board.
The AGM approved the compensation to the Board in accordance with the nomination committee’s proposal.
Ernst & Young AB was re-elected as auditor of Sobi for the period until the end of the next AGM.
Principles for remuneration for the management, long-term incentive program, authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants, and transfer of own shares
The AGM approved the guidelines for remuneration for the management proposed by the Board.
The AGM also approved the Board’s proposal regarding the implementation of a long-term incentive program, and hedging arrangements in respect of the program including a directed issue of no more than 496,760 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 1,497,125 own common shares to program participants.
The AGM also approved the Board’s proposal regarding the approval to authorise the Board to resolve on the issuance of new shares and/or convertible bonds and/or warrants. The number of shares that may be issued, the number of shares that convertible bonds may be converted into and the number of shares that may be subscribed for by the exercise of warrants, may not exceed 30,000,000 shares in total.
The Board’s proposal regarding transfer of no more than 158,563 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Share Program 2014, was also approved by the AGM.
For full details on each proposal adopted by the AGM please refer to "Related Documents" on this page.
Related information
- Minutes from AGM held May 4, 2017, 7.42 MB
- CEO's presentation at AGM 2017, 3.38 MB
- AGM Resolutions, 357 KB
- Complete Notice to Annual General Meeting 2017, 572 KB
- Proposal to AGM by Nomination Committé, 415 KB
- Motivated opinion re. proposals by the Nomination Committee, 330 KB
- Information about proposed members of the Board, 420 KB
- Proposal guidelines for remuneration to Management (item 16), 429 KB
- Proposal implementation of a longterm incentive program (item 17), 482 KB
- Proposal approval to authorise the issuance of new shares and/or convertible bonds and/or warrants (item 18), 300 KB
- Proposal transfer of own shares (item 19), 296 KB
- Report by the Sobi Board of Compensation & Benefits Committee's evaluation of remuneration to senior management, 320KB
- Board's Statement Swedish Companies Act 19:22, 306 KB
- Auditor's Statement Swedish Companies Act 8:54, 115 KB
- Proxy Form, 247 KB
Annual General Meeting 2016
The Annual General Meeting (AGM) in Swedish Orphan Biovitrum AB (publ), was held on Tuesday, May 24, 2016 at 3.00 p.m. in Wallenbergsalen, the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm, Sweden.
CEO's presentation at the AGM
The slides from CEO Geoffrey McDonough's presentation at the AGM is available for download under "Related Documents" on this page.
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits of SEK 4,882,438,248.
The board members and the chief executive officer were discharged from liability for the financial year 2015.
Election of Board of Directors, remuneration to the Directors and election of Auditor
The ordinary board members Annette Clancy, Matthew Gantz, Lennart Johansson, Helena Saxon and Hans GCP Schikan were re-elected and Håkan Björklund, Theresa Heggie and Jeffrey Jonas were elected as new board members. Håkan Björklund was elected chairman of the Board.
Håkan Björklund has an extensive international background in the life science industry, from both R&D and sales and marketing. He has experience of leading healthcare companies in expansive development phases. Håkan Björklund owns 15,800 shares in the company and is independent in relation to the company and its management and in relation to the company´s principal shareholders.
Theresa Heggie has several years’ of experience from a number of positions with a global responsibility within, among other things, sales and marketing of pharmaceuticals. Theresa Heggie does not have any shares in the company and is independent in relation to the company and its management and in relation to the company´s principal shareholders.
Jeffrey Jonas has more than 20 years’ of experience from research as well as marketing within the pharmaceuticals and healthcare industries. Jeffrey Jonas does not have any shares in the company and is independent in relation to the company and its management and in relation to the company´s principal shareholders.
The AGM approved the compensation to the Board in accordance with the nomination committee’s proposal.
Ernst & Young was re-elected as auditor of Sobi until the end of the AGM 2017.
Principles for remuneration for the management, long-term incentive programme, authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants, and transfer of own shares
The AGM approved the proposed guidelines for remuneration for the management.
The AGM also approved the Board’s proposal regarding the implementation of a long-term incentive programme, and hedging arrangements in respect of the programme including a directed issue of no more than 188,142 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 1,276,826 own common shares to programme participants.
The AGM also approved the Board’s proposal regarding the approval to authorise the Board to resolve on the issuance of new shares and/or convertible bonds and/or warrants. The number of shares that may be issued, the number of shares that convertible bonds may be converted into and the number of shares that may be subscribed for by the exercise of warrants, may not exceed 30,000,000 shares in total.
The Board’s proposal regarding transfer of no more than 303,346 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Share Programme 2013, was also approved by the AGM.
For full details on each proposal adopted by the AGM please refer to "Related Documents" on this page.
Related information
- Minutes from AGM held May 24, 2016, 3.99 MB
- CEO's presentation at AGM 2016, 2.75 MB
- AGM Resolutions, 121 KB
- Complete Notice to Annual General Meeting 2016, 574 KB
- Proposal re. guidelines for remuneration to Management (item 16), 340 KB
- Proposal re. implementation of a longterm incentive program (item 17), 493 KB
- Proposal re. the approval to authorise the issuance of new shares and/or convertible bonds and/or warrants (item 18), 324 KB
- Proposal re. transfer of own shares (item 19), 317 KB
- Nomination Committee's proposal to AGM, 374 KB
- Motivated opinion re. proposals by the Nomination Committee, 347 KB
- Information about proposed members of the Board, 438 KB
- Report by Sobi Board of Compensation & Benefits Committee's evaluation of remuneration to senior management, 246 KB
- Board's Statement Swedish Companies Act 19:22, 327 KB
- Auditor's Statement Swedish Companies Act 8:54, 125 KB
- Proxy Form, 251 KB
Annual General Meeting 2015
The Annual General Meeting (AGM) in Swedish Orphan Biovitrum AB (publ), was held on Tuesday, June 30, 2015 at 2.00 p.m. in Wallenbergsalen, the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm, Sweden.
CEO's presentation at the AGM
The slides from CEO Geoffrey McDonough's presentation at the AGM is available for download under "Related Documents" on this page.
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits of SEK 4,561,601,316 .
The board members and the chief executive officer were discharged from liability for the financial year 2014.
Election of Board of Directors, remuneration to the Directors and election of Auditor
The ordinary board members Adine Grate Axén, Annette Clancy, Matthew Gantz, Bo Jesper Hansen, Lennart Johansson, Helena Saxon, Hans GCP Shikan and Hans Wigzell were re-elected and Bo Jesper Hansen was re-elected chairman of the Board.
The AGM approved the compensation to the Board in accordance with the nomination committee’s proposal.
Ernst & Young was elected as auditor of Sobi until the end of the annual general meeting 2016.
Principles for remuneration for management, long-term incentive program and transfer of own shares
The AGM approved the proposed guidelines for remuneration for the management.
The AGM also approved the Board’s proposal regarding the implementation of a long-term incentive program, and hedging arrangements in respect of the program including a directed issue of no more than 1,036,856 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 1,630,976 own common shares to program participants.
The Board’s proposal regarding transfer of no more than 193,233 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Share Program 2012, was also approved by the AGM.
For full details on each proposal adopted by the AGM please refer to "Related Documents" on this page.
Related information
- Minutes AGM, 30 June, 2015, 3.21 MB
- CEO's presentation at AGM 2015, 2.47 MB
- AGM resolutions, 118 KB
- Complete Notice to Annual General Meeting 2015, 483 KB
- Proposal re. guidelines for remuneration to Management (item 16), 289 KB
- Proposal re. implementation of a longterm incentive program (item 17), 429 KB
- Proposal re. transfer of own shares (item 18), 277 KB
- Nomination Committee's proposal to AGM, 300 KB
- Motivated opinion re. proposal by the Nomination Committee, 272 KB
- Information about proposed members of the Board, 372 KB
- Report by Sobi Board on Compensation & Benefits Committee's evaluation of remuneration to senior management, 196 KB
- Board's Statement Swedish Companies Act 19:22, 264 KB
- Auditor's Statement Swedish Companies Act 8:54, 298 KB
- Proxy Form, 211 KB
Annual General Meeting 2014
The Annual General Meeting (AGM) in Swedish Orphan Biovitrum AB (publ) was held on Thursday, May 8, 2014 at 4.00 p.m. in Wallenbergsalen, at Kungliga Ingenjörsvetenskapsakademien (IVA), Grev Turegatan 16, Stockholm, Sweden.
CEO’s presentation at the AGM
The slides from CEO Geoffrey McDonough’s presentation at the AGM is available for download under “Related Documents”.
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits of SEK 4,672,982,798.
The board members and the chief executive officer were discharged from liability for the financial year 2013.
Election of Board of Directors, remuneration to the Directors and election of Auditor
The ordinary board members Adine Grate Axén, Matthew Gantz, Bo Jesper Hansen, Lennart Johansson, Helena Saxon, Hans GCP Schikan and Hans Wigzell were re-elected to the Board. Annette Clancy was elected as new board member. Bo Jesper Hansen was re-elected chairman of the Board.
The AGM approved the compensation to the Board in accordance with the nomination committee’s proposal.
Ernst & Young was elected as new auditor of Sobi until the end of the annual general meeting 2015.
Principles for remuneration for the management, long-term incentive program and transfer of own shares
The AGM approved the proposed guidelines for remuneration for the management.
The AGM also approved the Board’s proposal regarding the implementation of a long-term incentive program, and hedging arrangements in respect of the program including a directed issue of no more than 396,180 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 1,100,235 own common shares to program participants.
The Board’s proposal regarding transfer of no more than 338,766 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Share Program 2011 and the CEO Share Program 2011, was also approved by the AGM.
For full details on each proposal adopted by the AGM please refer to "Related Documents".
Related information
- Minutes AGM 8 May, 2014, 3.84 MB
- CEO presentation slides AGM 2014, 2.51 MB
- AGM Resolutions, 127 KB
- Complete Notice to Annual General Meeting 2014, 552 KB
- Proposal re. guidelines for remuneration to Management (item 16), 359 KB
- Proposal re. implementation of a long-term incentive program (item 17), 492 KB
- Proposal re. transfer of own shares (item 18), 349 KB
- Nominations Committee's proposal to AGM, 376 KB
- Motivated opinion re. proposal by the Nomination Committee, 316 KB
- Information about proposed members of the Board, 433 KB
- Report by Sobi Board on Compensation & Benefits Commmittee's evaluation of remuneration to senior management, 308 KB
- Board's Statement Swedish Companies Act 19:22, 320 KB
- Auditor's Statement Swedish Companies Act 8:54, 73 KB
- Proxy Form, 209 KB
Annual General Meeting 2013
The Annual General Meeting (AGM) in Swedish Orphan Biovitrum AB (publ) took place on Friday 26 April 2013 at 4.00 p.m. in Wallenbergsalen, at Kungliga Ingenjörsvetenskapsakademien (IVA), Grev Turegatan 16, Stockholm, Sweden.
CEO's presentation at the AGM
The slides from CEO Geoffrey McDonough's presentation at the AGM is avaliable for download under related documents.
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statement and the balance sheet and approved the proposal to carry forward the retained profits of SEK 4,659,221,805.
The board members and the chief executive officers were discharged from liability for the financial year 2012.
Election of Board of Directors, remuneration to the Directors and election of Auditor
The ordinary board members Adine Grate Axén, Matthew Gantz, Bo Jesper Hansen, Lennart Johansson, Helena Saxon, Hans GCP Schikan and Hans Wigzell were re-elected. Bo Jesper Hansen was re-elected chairman of the Board.
The AGM approved the compensation to the Board in accordance with the nomination committee’s proposal.
PricewaterhouseCoopers AB was elected auditor of Sobi until the end of the annual general meeting 2014.
Nomination Committee
The AGM approved the proposed instructions and charter for the nomination committee.
Principles for remuneration for the management, long-term incentive program and transfer of own shares
The AGM approved the proposed guidelines for remuneration for the management.
The AGM also approved the Board’s proposal regarding the implementation of a long-term incentive program, and hedging arrangements in respect of the program including a directed issue of no more than 754,912 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 1,719,238 own common shares to program participants.
The Board’s proposal regarding transfer of no more than 135,082 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Share Program 2010, was also approved by the AGM.
Related information
- Minutes AGM April 26, 2013, 3.57 MB
- CEO Speech AGM 2013, 1.81 MB
- Press release AGM resolutions 2013, 103 KB
- Complete Notice to Annual General Meeting 2013, 358 K
- Proposal re. guidelines for remuneration to Management Team (item 16), 101 KB
- Proposal re. instructions and charter for the Nomination Committee (item 17), 79 KB
- Proposal re. implementation of a long-term incentive program (item 18), 253 KB
- Proposal re. transfer of own shares (item 19), 96 KB
- Nomination Committee's proposal to AGM, 77 KB
- Motivated opinion re. Nomination Committee's proposal, 177 KB
- Information proposed Members of the Board, 93 KB
- Board's statement Swedish Companies' Act 19:22, 129 KB
- Auditor's Statement Swedish Companies' Act 8:54, 714 KB
- Proxyform, 209 KB
Annual General Meeting 2012
The Annual General Meeting (AGM) in Swedish Orphan Biovitrum AB (publ) took place on Thursday 26 April 2012 at 4.00 p.m. in Wallenbergsalen, at Kungliga Ingenjörsvetenskapsakademien (IVA), Grev Turegatan 16, Stockholm, Sweden.
CEO's presentation at the AGM
The slides from CEO Geoffrey McDonough's presentation at the AGM is avaliable for download under related documents.
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statement and the balance sheet and approved the proposal to carry forward the retained profits of SEK 4,583,105,488.
The board members and the chief executive officers were discharged from liability for the financial year 2011.
Election of Board of Directors, remuneration to the Directors and election of Auditor
The ordinary board members Adine Grate Axén, Bo Jesper Hansen, Lennart Johansson, Helena Saxon, Hans GCP Shikan and Hans Wigzell were re-elected and Matthew Gantz was elected as new board member. Bo Jesper Hansen was re-elected chairman of the Board.
Matthew Gantz was born 1965 and has a BA from Princeton University and an MBA from Harvard Business School. He is Regional US Executive Vice President and General Manager US in BTG, British Technology Group. Prior to BTG, he was Founder and CEO of Acureon Pharmaceuticals, President and CEO of Hydrabiosciences Inc, VP Europe for Chiron’s Biopharmaceutical Division and General Manager for PathoGenesis Europe. Prior to Chiron/PathoGenesis, Matthew held a variety of US sales and marketing roles at Abbott Laboratories Diagnostics Division. Matthew Gantz does not hold any shares or options in the company. He is independent in relation to the company and its management and in relation to the company’s principal shareholders.
The AGM approved the compensation to the Board in accordance with the nomination committee’s proposal.
PricewaterhouseCoopers AB was elected auditor of Sobi until the end of the annual general meeting 2013.
Nomination Committee
The AGM approved the proposed instructions and charter for the nomination committee.
Principles for remuneration for the management, long-term incentive program and transfer of own shares
The AGM approved the proposed guidelines for remuneration for the management.
The AGM also approved the Board’s proposal regarding the implementation of a long-term incentive program, and hedging arrangements in respect of the program including a directed issue of no more than 1,655,136 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 1,480,136 own common shares to program participants.
The Board’s proposal regarding transfer of no more than 88,551 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Share Program 2009, was also approved by the AGM.
For full details on each proposal adopted by the AGM please refer to the related documents list on this page.
Related information
- Minutes from AGM, April 26, 2012, 6.44 MB
- CEO presentation at AGM, 1.33 MB
- PR Resolutions from AGM 2012, 336 KB
- Complete Notice to AGM 2012, 330 KB
- Proposal re. guidelines for remuneration for the management (item 16), 84 KB
- Proposal re. implementation of a long-term incentive program (item 18), 251 KB
- Proposal re. transfer of own shares (item 19), 78 KB
- Board's Statement Swedish Companies Act 19:22, 144 KB
- Board evaluation of remuneration to senior management, 87 KB
- Nomination Committee's proposal to the AGM, 59 KB
- Auditor's statement ABL 8:54 re compliance with guidelines remuneration to senior management, 83 KB
- Motivated opinion re. Nomination Committee's proposal, 196 KB
- Information proposed board members, 86 KB
- Proxy Form, 272 KB
Extra Annual General Meeting 2011
An Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, was held on Wednesday August 24, 2011 at 4.00 p.m, IVA Konferenscenter - Wenströmsalen, Grev Turegatan 16, Stockholm.
Related information
- Minutes from Extra General Meeting Aug 24, 2011
- Resolutions Extra General Meeting Aug 24, 2011
- Notice of Extraordinary General Meeting
- Proxy Form
- Instruction for Proxy
- The board of directors' proposal re a performance based, long-term share program for the CEO (the "CEO Share Program 2011")
- The board of directors' proposal for resolutions on a) an authorization to issue series C shares, b) an authorization to repurch
- The board of directors' proposal re guidelines for remuneration for the management
- The board of directors' statement in accordance with Ch 19, Sec 22-23 of the Swedish Companies Act
- The board of directors' statement in accordance with Ch 19, Sec 24 of the Swedish Companies Act
- Auditor's statement in accordance with Ch 19, Sec 24 of the Swedish Companies Act
- Annual Report 2010
- Auditor's Report for 2010
Annual General Meeting 2011
The shareholders in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the “Meeting”), to be held on Thursday 28 April 2011 at 4.00 p.m. in Wallenbergsalen at Kungliga Ingenjörsvetenskapsakademien (IVA), Grev Turegatan 16, Stockholm, Sweden.
*Due to applicable legal restrictions, electronic versions of these materials are not directed at or accessible by persons located in the United States, Australia, Canada, Japan Hong Kong, Singapore, South Africa, Switzerland, USA or in any other state or jurisrisdiction where the offer or sale of the rights or shares is not permitted. We apologize for any inconvenience this may cause.
Resolutions from AGM (This document contains information on the rights issue - see more info above at *)
Notice of Annual General Meeting (This document contains information on the rights issue - see more info above at *)
Related information
- Minutes from Annual General Meeting, April 28, 2011
- CEO's presentation (Swedish)
- The board of directors’ statement in accordance with Chapter 19 Section 22 of the Swedish Companies Act
- The board of directors’ proposal regarding guidelines for remuneration for the management (item 16)
- Instructions and charter for the Nomination Committee (item 17)
- The board of directors’ proposal regarding amendment of the articles of association (item 18)
- The board of directors’ proposal regarding performance based, long-term share program (item 20)
- Resolution regarding transfer of own shares (item 21)
- Report by the Board of Directors of Swedish Orphan Biovitrum AB (publ) on the Compensation & Benefits Committee's evaluation of
- Auditor's report regarding compensation
- Nomination Committee proposal
- Nomination Committee motivated opinion
- Information about proposed board members
- The board of directors’ proposal regarding amendment of the articles of association (item 19) (This document contains informatio
Annual General Meeting 2009
The annual general meeting was held on Tuesday 28 April 2009 at 4.00 p.m. at Musiksalen, Norra Latin, Drottninggatan 71B, Stockholm, Sweden.
Related information
- Notice of Annual General Meeting 2009
- Minutes from Annual General Meeting 2009
- The board of directors’ proposal regarding guidelines for remuneration for the management (item 16)
- The board of directors’ proposal regarding authorization for the board of directors to issue new shares (item 19)
- Instructions and charter for the Nomination Committee (item 17)
- The board of directors’ of Biovitrum AB (publ) statement in accordance with Chapter 19 Section 22 of the Swedish Companies Act
- The board of directors’ proposal regarding amendment of the articles of association (item 18)
- The board of directors’ proposal regarding performance based, long-term share program (item 20)
- Information about proposed board members
- The nomination committee’s motivated opinion regarding proposal for board of directors
- Nomination committees proposal
- Auditors report